S&P/ASX 200 Materials Index (ASX: XMJ) shares — dominated by Australian miners — are 10% higher in 2026.

This compares to a 1.6% decline for the benchmark S&P/ASX 200 Index (ASX: XJO) in the calendar year to date (YTD).

The ASX 200 materials sector rose by 32% last year, largely due to soaring share prices for mining companies. 

This year, ASX mining shares have fluctuated due to a metals sell-off in late January and today’s continuing global oil shock.

The long-term picture is that Australia is in the midst of a new mining boom powered by a new commodities super cycle.

If you’re looking for investment opportunities, here are 2 ASX mining shares recommended by experts this week.

Maronan Metals Ltd (ASX: MMA)

The Maronan Metals share price is 37 cents, up 2.8% today and down 15% YTD.

The company is developing the Maronan silver-lead and copper-gold deposit in the Cloncurry region of northwest Queensland.

The mine is one of Australia’s largest undeveloped silver-lead-copper and gold deposits.

On The Bull this week, Tony Locantro from Alto Capital has a speculative buy rating on this ASX mining share. 

Locantro explains: 

The company recently secured about $22 million in strategic funding, strengthening its balance sheet and supporting an expanded drilling program. A second drill rig has now been deployed to accelerate resource growth and improve confidence in the starter zone.

The recent separation from Red Metal Ltd (ASX: RDM) has also simplified the investment case and increased market visibility.

While development stage projects carry funding and execution risk, the combination of a high quality resource, strong financial backing and upcoming catalysts support a speculative buy recommendation.

Deterra Royalties Ltd (ASX: DRR)

The Deterra Royalties share price is $4.35, down 0.1% today and up 5.2% YTD. 

Deterra has a portfolio of 14 royalties and royalty-like offtake assets in 7 countries.

It is invested in iron ore, lithium, mineral sands, copper, molybdenum, and gold.

Mining royalties are agreements in which a third party provides financing to a miner in exchange for a portion of future revenues or production.

One of Deterra’s royalty assets is Mining Area C (MAC) in the Pilbara, owned by BHP Group Ltd (ASX: BHP).

Investing in Deterra Royalties is an alternative to directly buying ASX mining shares.

Damien Nguyen from Morgans recommends buying Deterra Royalties shares.

Here’s why:

DRR’s royalty structure provides highly leveraged, low cost exposure to iron ore volumes with no operational risk, capital expenditure, or direct commodity price hedging.

As production ramps up further at Mining Area C (MAC) and BHP Group continues to invest in expanding capacity, Deterra’s royalty stream is set to grow over the medium term.

The balance sheet is conservatively managed, and the company has a strong track record of returning capital to shareholders through fully franked dividends.

The market appears to be discounting near term iron ore price softness more heavily than the long term volume growth story warrants.

We see the recent share price as an attractive entry point.

The post 2 ASX mining shares to buy: experts appeared first on The Motley Fool Australia.

More reading

• 5 ASX 200 shares downgraded by the experts this week
• 2 ASX tech shares I’d buy that aren’t Xero or WiseTech
• This ASX income stock has a 4.75% yield and pays out monthly
• What’s Core Lithium’s big news today?
• Why this ASX 200 stock is crashing after doubling in a year

Motley Fool contributor Bronwyn Allen has positions in BHP Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Sigma Healthcare Ltd (ASX: SIG) shares have tumbled further into the red in Thursday’s lunchtime trade.

At the time of writing, the ASX healthcare company’s shares are down around 2% to $2.72 a piece.

The shares have now fallen just over 7% since Tuesday, shedding gains made over the past couple of months.

Sigma Healthcare shares are down around 8% year to date. They’re now roughly 14% below their trading level this time last year.

Why are Sigma Healthcare shares in the spotlight?

There isn’t any company-specific price-sensitive news out of Sigma Healthcare this week to explain the share price slump.

It looks like investors are selling off their shares on the back of news that the Chemist Warehouse owner is in preliminary talks to buy the major UK health, beauty, and pharmacy retail chain, Boots.

Yesterday, there were reports that the company has entered into preliminary talks to buy the UK’s largest independent pharmaceutical chain as part of its plan to move overseas.

According to reports in the Financial Times, Boots owner Sycamore Partners has been approached by several different retailers to take control of the business.

Sigma is understood to be among the interested partners. Along with Canada’s supermarket chain Loblaws and pharmacy retailer Shoppers Drug Mart.

In a note to the ASX, the company responded to media speculation. It also confirmed it is in preliminary talks with Boots. It said:

Sigma Healthcare Limited (Sigma) refers to the recent media speculation regarding the sale process of The Boots Group (Boots). Sigma continuously reviews opportunities that would create value for shareholders and has engaged in preliminary discussions in relation to the sale process. There is no certainty that any transaction will eventuate.

Clearly, investors aren’t thrilled with the media speculation. The share price closed over 5% lower for the day after the announcement, and investors have continued selling today.

Why are investors concerned?

It isn’t entirely clear. But I’d speculate that the sell-off doesn’t necessarily mean investors aren’t happy about a potential acquisition. It’s more likely that investors are concerned about potential execution risk, deal size, and timing.

Boots is currently valued at around AU$14 billion.

Keeping in mind that Sigma Healthcare completed its merger with Chemist Warehouse in early 2025. The combined business controls nearly 1,000 stores and has a valuation exceeding $30 billion. 

Generally, investors expect businesses to fully integrate after a major acquisition before considering another major transaction. 

What’s the outlook for Sigma Healthcare shares?

According to Market Index data, brokers remain bullish on the outlook for the shares over the next 12 months.

Data updated today, 11th of June, shows the majority (six out of seven) have a buy rating on the stock. They tip a potential 20% upside to an average target price of $3.26, at the time of writing.

The post Why are Sigma Healthcare shares in the spotlight this week? appeared first on The Motley Fool Australia.

More reading

• Why Evolution Mining, REA Group, Sigma Healthcare, and TechnologyOne shares are tumbling today
• 3 high-quality Australian shares I’d buy with $10,000
• My 3 best ASX 200 blue-chip shares to buy in June
• 4 ASX 200 shares rated a strong buy and with upsides of up to 51%
• How to get wealthy investing $300 a month into ASX shares

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Westpac Banking Corp (ASX: WBC) shares are sliding today.

Shares in the S&P/ASX 200 Index (ASX: XJO) bank stock closed yesterday trading for $35.41. As we eye the Thursday lunch hour, shares are changing hands for $34.94 apiece, down 1.3%.

National Australia Bank Ltd (ASX: NAB) shares are taking a hit as well. The NAB share price closed yesterday at $36.33. At the time of writing, shares are trading for $35.93 each, down 1.1%.

For some context, the ASX 200 is down 0.3% at this same time amid a broader global stock market retreat following renewed military strikes in the Middle East.

Unfortunately, today’s underperformance for these big four banks has been par for the course in 2026, with both ASX 200 bank stocks materially trailing the 1.2% year-to-date losses posted by the benchmark index.

Indeed, Westpac shares have slumped 10.3% this calendar year. Losses that will only be marginally eased by the fully-franked 77 cent per share dividend the bank will pay eligible stockholders on 26 June.

Westpac stock traded ex-dividend on 8 May, so investors selling today, who held the stock at market close on 7 May, will receive that passive income payout.

NAB shares have had an even tougher run this year, down 15.2% since 2 January.

NAB will pay out its 85-cent per share fully-franked interim dividend on 2 July. NAB shares traded ex-dividend on 7 May, so that payout will go to investors who held the stock at market close on 6 May.

And looking ahead, MPC Markets’ Mark Gardner forecasts that both ASX 200 bank stocks are likely to face more headwinds over the coming months (courtesy of The Bull).

Here’s why.

Time to exit Westpac shares?

“Westpac has a strong retail franchise, but the valuation appears stretched,” Gardner said. “Consensus targets imply downside from current levels.”

Summarising his sell recommendation on Westpac shares, he concluded:

The bank has made progress on simplifying its operations and cutting costs, but, in our view, earnings growth is still expected to lag the broader Australian market. The bank is up against competitive pressures and the risk of softer credit conditions. Investors may want to consider taking a profit at these levels.

Should I sell NAB shares today?

Alongside his bearish outlook for Westpac shares, Gardner also issued a sell recommendation for NAB shares.

“NAB remains a quality banking franchise, but the near-term earnings outlook is under pressure,” he said.

Gardner noted the attractive passive income on offer from NAB shares, but pointed to some concerning issues from its H1 FY 2026 results.

According to Gardner:

The bank’s first half net profit in fiscal year 2026 missed analyst expectations, with bad debt provisions and one-off charges weighing on the result. The dividend remains attractive, but valuation support looks less convincing if earnings momentum continues to soften.

Explaining his sell recommendation for NAB shares, he concluded:

In our view, the bank faces the challenges of margin pressure, higher credit risk and slower profit growth. We prefer to reduce exposure and direct capital towards stronger growth opportunities elsewhere.

The post Sell alert! Why this expert is calling time on NAB and Westpac shares appeared first on The Motley Fool Australia.

More reading

• Hedge funds are shorting the big four bank shares. Should investors be worried?
• What are the big 4 banks worth as the housing market falters?
• Sell alert! Why this expert is calling time on Westpac and CBA shares
• The next RBA interest rates move will be down, NAB says
• Buy, hold, sell: Resmed, Goodman Group, Westpac shares

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

There are a decent number of options in the tech sector for investors to choose from.

But one ASX tech stock flying under the radar that could be worth getting acquainted with has been named in this article.

Let’s see why Bell Potter thinks it could be a buy this week.

Which ASX tech stock?

The tech stock that is being tipped as a buy is Cogstate Ltd (ASX: CGS).

It is a healthcare technology company focused on optimising brain health assessments, predominantly for clinical trials of novel medicines.

Bell Potter notes that the company mostly generates revenue from providing services to biopharma customers conducting clinical trials in central nervous system (CNS) indications. This includes Alzheimer’s disease.

It notes that the company held an investor webinar this week, which provided insights into the business and its Orexin opportunity. It said:

As expected, there was minimal new financial data, but rather the presentation focused on qualitative aspects regarding recent tailwinds from (1) channel partnerships with Medidata and others, (2) increased use of CGS’s central rating capabilities, and (3) newer indications such as narcolepsy and psychiatry where CGS has been winning more work recently. These three inter-related aspects have been driving contract sales growth and diversification over the last ~12 months (refer to our latest Q3 update for more detail).

Regarding point #3, we have reviewed the clinical-stage drug development landscape in narcolepsy and other orexin-related conditions. We conclude the orexin market reflects at least a ~US$30-40m contract opportunity for CGS over the coming ~3-4 years, for which CGS is very well placed to continue being a leading provider for endpoint management and trial monitoring solutions. Additionally, CGS continues to benefit from partners such as Medidata who are bringing in more contract opportunities, i.e. more ‘shots on goal’. These partners are clearly starting to convert into additional wins for CGS (e.g. 62% of sales contracts in 2Q FY26 were driven by these partners).

In light of this, the broker remains very positive on the ASX tech stock and is recommending it to clients.

How much upside does Bell Potter see?

According to the note, Bell Potter has retained its buy rating and $3.20 price target on Cogstate’s shares.

Based on its current share price of $2.75, this implies potential upside of 16% for investors over the next 12 months.

While its shares trade on multiples that are in line with peers, Bell Potter believes it has a stronger growth outlook. It commented:

BUY recommendation and $3.20 PT remains unchanged. CGS is trading on ~13.5x EV/EBITDA based on our FY27e, which is in line with the global CRO peer avg, however CGS has a far more attractive growth outlook than these peers.

The post Bell Potter is recommending this ASX tech stock as a buy appeared first on The Motley Fool Australia.

More reading

• Why are Sigma Healthcare shares in the spotlight this week?
• Sell alert! Why this expert is calling time on NAB and Westpac shares
• Is it time to get greedy with Pro Medicus shares?
• If you invested $10,000 in Megaport shares in April, here’s how much you’d have now
• Are Wesfarmers shares a buy, sell or hold after this week’s update?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cogstate. The Motley Fool Australia has positions in and has recommended Cogstate. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Pro Medicus Ltd (ASX: PME) shares are climbing higher on Thursday.

At the time of writing, the shares are up slightly by about 1% and are changing hands at $162.82 each. Today’s increase means the shares are now nearly 23% higher so far in June.

The rebound is good news for investors after a huge sell-off over the past year. Pro Medicus shares are still 51% below their all-time peak recorded in July last year and are also down 27% year to date.

The company was just one of many ASX healthcare shares that were caught up in a severe sector-wide downturn in early 2026. The healthcare sector came under significant pressure due to macroeconomic factors, a weaker US dollar, rising inflation, higher cost of living, and regulatory uncertainty.

Why are Pro Medicus shares rebounding this month?

Pro Medicus shares have rebounded strongly since the health imaging technology company announced three new contract wins and renewals in June alone.

Earlier this month, Pro Medicus revealed that its wholly owned US subsidiary, Visage Imaging, had signed a five-year, A$28 million contract renewal with Allegheny Health Network (AHN) and a new A$16 million, seven-year contract with TidalHealth.

Later the same week, the company confirmed that Visage Imaging has signed a five-year A$16 million contract renewal, including the additions of Visage 7 Workflow and Visage 7 Cardiology Imaging, with The Ohio State University Wexner Medical Center (OSUWMC). 

This latest renewal brings the total renewals for the financial year to A$141 million. The total of new contracts comes to around A$280 million for FY26. 

Is it time to buy?

According to experts, it’s time to get greedy while Pro Medicus shares are cheap.

Market Index data shows the majority of brokers have a buy rating on the stock, and they tip a 20% upside to an average target price of $193.92. 

The data is similar on TradingView. Out of 15 analysts, 12 have a buy or strong buy rating, and two have a hold rating on Pro Medicus shares. The average $189.47 target price implies a 17% upside at the time of writing. The maximum $245 target price implies the shares could climb another 51% over the next 12 months.

Macquarie is one broker with a buy rating on the ASX healthcare company, with a $221 target. The broker said recent contract wins have supported market sentiment following the tech sell-off due to AI fears. The team said they think the business size, variety, and increasing upsell to cardiology support the high target price. 

The analyst team at Morgans is also positive about Pro Medicus shares. The broker said the company is executing well and is in a structurally strong competitive position. Morgans has a buy rating and $210 target price on the shares.  

The post Is it time to get greedy with Pro Medicus shares? appeared first on The Motley Fool Australia.

More reading

• Why might Pro Medicus shares soon be under pressure?
• 7 ASX shares set to soar 30% to 90% in 12 months: experts
• Why Chalice Mining, CSL, Megaport, and Pro Medicus shares are racing higher
• 7 ASX 200 shares with strengthened buy ratings this week
• 3 ASX 200 stocks racing higher in this week’s slumping market

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Macquarie Group and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Megaport Ltd (ASX: MP1) shares have been one of the S&P/ASX 200 Index (ASX: XJO)’s big comeback trades in 2026.

The Megaport share price is up 2.38% to $18.48 at the time of writing.

That puts the ASX tech share up around 15% over the past week and almost 60% since the start of the year.

But the biggest move has come from the lows in April.

Megaport shares hit an intraday low of $6.40 on 13 April before closing that session at $6.86.

Since then, the stock has staged a major rebound, helped by new AI infrastructure contracts and renewed broker interest.

The rally even took Megaport shares to a 52-week high of $21.16 last Friday.

So, what would a $10,000 investment near the April low be worth today?

Why Megaport shares have taken off

The main driver has been a significant shift in sentiment toward Megaport’s growth outlook.

The company recently announced four new AI infrastructure contracts with a total contract value of approximately $458.9 million.

Those contracts have helped put Megaport back in front of investors looking for ASX exposure to AI, cloud infrastructure, and data centre demand.

Megaport also launched a fully underwritten $827.3 million entitlement offer to help fund the capital expenditure needed to deliver the new work and build out its global GPU pool.

The retail entitlement offer opened today and is priced at $14.30 per new share.

That’s below the current share price, which helps explain why eligible shareholders may be paying close attention.

Furthermore, Megaport narrowed its FY26 revenue guidance to between $307 million and $315 million.

How much would that investment be worth?

If an investor had put $10,000 into Megaport shares at the April intraday low of $6.40, they would have bought about 1,562 shares.

At today’s price of $18.48, that holding would now be worth about $28,875.

That means the investment would have increased by roughly $18,875 in less than two months, before brokerage and any tax.

Even if the investor bought at the 13 April closing price of $6.86, the result would still be significant.

A $10,000 investment at that price would have bought about 1,458 shares. At today’s price, that parcel would be worth about $26,940.

Either way, it shows how quickly sentiment has turned around for Megaport shares.

Foolish bottom line

Megaport has delivered an extraordinary short-term gain since April.

But after such a fast rally, investors are no longer buying the same beaten-down stock they were looking at two months ago.

UBS has reportedly lifted its price target to $24.20, while Macquarie has a higher target of $27.80.

Morgans has been more cautious, downgrading the stock to accumulate while still lifting its target to $21.

That suggests brokers still see upside in Megaport, but most of the gains appear to be already behind it.

The post If you invested $10,000 in Megaport shares in April, here’s how much you’d have now appeared first on The Motley Fool Australia.

More reading

• Megaport launches retail entitlement offer after $827 million capital raise
• Megaport shares soar 194% in 2 months. What’s ahead for the remainder of 2026?
• 2 ASX growth shares to buy with big growth potential!
• Up 90% in a month, why did Megaport shares just get downgraded?
• Why are ASX 200 tech stocks like WiseTech, Life360 and Xero shares getting hammered on Tuesday?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group and Megaport. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Wesfarmers Ltd (ASX: WES) is a staple blue-chip stock in many Australian investors’ portfolios, and it’s not hard to see why.

The company has a strong stable of retail brands across its Bunnings, Kmart, and Officeworks operations and is also diversified into lithium mining through its Western Australian Mt Holland operations.

While the shares are broadly flat over the past year, according to CMC Markets data, Wesfarmers has returned a compound 22.7% over three years and 11.4% over five.

So are the shares good value at the moment?

AI the focus of strategy day

Wesfarmers, earlier this week, held a strategy briefing day where it laid out its plans for the future.

One of the key messages that came out of the day, and which would be implemented across the business, was the use of artificial intelligence (AI) to help team members do their jobs, increase the effectiveness of marketing, and improve supply chain operations.

Within Bunnings, the company said it could use AI to help people plan and carry out do-it-yourself projects, while online, it would enable customers to find and buy products more easily.

The company will also be bolstering its in-store media offerings, growing the network to more than 560 in-store screens across more than 250 stores.

Within the Kmart division, the company now has 16 stores trading in its new Kmart Plan C+ format and expects to grow that number to 40 by the end of FY27.

Wesfarmers shares looking fully-priced

Regarding how the strategy briefing was received by analysts, all three I surveyed issued a neutral recommendation on the stock following the strategy day.

The team at Jarden said it was a steady-as-she-goes message.

They added:

WES’s Strategy Day provided a consistent, clear message with no trading updates and a strategic agenda that was iterative vs. a step-change. The overall tone was one of optimism and readiness to be a leader across digital, AI and data, as opposed to its historical position as a fast-follower (i.e. online). We came away more positive, but are cutting FY27 EPS c3%, while raising FY28+ modestly.

Jarden has a neutral rating on the stock with a 12-month price target of $79.30.

Macquarie has a more bullish price target of $85 on Wesfarmers shares, but also has a neutral rating, saying there were no near-term catalysts that would see the stock break out.

UBS, meanwhile, has an $84 price target on Wesfarmers, upgrading that from $81 on the company’s increasing confidence in the retail growth outlook.

Wesfarmers shares are currently changing hands for $83.35. The company is valued at $94.7 billion.

The post Are Wesfarmers shares a buy, sell or hold after this week’s update? appeared first on The Motley Fool Australia.

More reading

• I love Wesfarmers shares. Here’s why I’m not buying more
• How high could Wesfarmers shares go?
• Why Develop Global, IDP Education, JB Hi-Fi, and Wesfarmers shares are pushing higher today
• Why are Wesfarmers shares pushing higher today?
• 5 things to watch on the ASX 200 on Wednesday

Motley Fool contributor Cameron England has positions in Wesfarmers. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group and Wesfarmers. The Motley Fool Australia has recommended Macquarie Group and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Are you on the hunt for outsized returns for your ASX share portfolio?

If you are, it could be worth looking at the shares in this article that Morgans has been recommending to clients. Here’s what the broker is saying:

GQG Partners Inc (ASX: GQG)

The first ASX share to look at is GQG Partners. Morgans has put an accumulate rating and $1.64 price target on this fund manager’s shares this week.

Based on its current share price of $1.45, this implies potential upside of 13% for investors over the next 12 months. However, a dividend yield of around 10% is also expected, boosting the total potential return to 23%. It commented:

GQG has provided a May FUM update. Overall, monthly outflows appear to be stabilising in the -A$1.5bn to -A$2.0bn range, although investment performance remains highly volatile. While FUM is effectively flat calendar year-to-date, with outflows offset by positive market movements, we acknowledge it will be difficult for GQG to re-rate until the current outflow cycle ends. We lower our GQG FY26F/FY27F EPS forecasts by 1%-5% and reduce our price target to A$1.64 (from A$1.92). While the near-term operating environment remains difficult, we continue to see long-term value in the GQG franchise, trading at ~9x FY1 PE with a ~10% dividend yield. ACCUMULATE.

Helloworld Travel Ltd (ASX: HLO)

Another ASX share the broker has been looking at is Helloworld. Morgans has put a buy rating and $2.23 price target on this travel company’s shares.

Based on its current share price of $1.39, this implies potential upside of around 60% for investors over the next 12 months. It said:

Given recent profit downgrades from other travel industry peers due to the conflict in the Middle East, HLO’s downgrade wasn’t a surprise. It has revised its FY26 EBITDA guidance by 11-14%. We have downgraded our forecasts. We assume that the conflict and a subdued consumer environment continue to impact the 1H27, followed by a strong recovery in the 2H27. This could prove conservative given HLO’s strong 1Q27 bookings. We are buyers of HLO during this period of short-term uncertainty and share price weakness because when operating conditions ultimately improve, both its earnings and share price leverage to the upside will be material.

Tetratherix Ltd (ASX: TTX)

A higher risk option for investors is regenerative medicine company Tetratherix.

Morgans has a speculative buy rating and $7.15 price target on the company’s shares. Based on its current share price of $5.31, this implies potential upside of approximately 35%. It commented:

TTX successfully completes a placement to fund the expansion of its production facility and build on its customer success team. We have updated our model to reflect the new capital and take a more optimistic stance on FDA approval for its dental/orthopedic products. Independent research shows TTX’s drug delivery platform can safely carry and protect fragile drugs when delivered through the nose. Future licensing opportunities are likely. Our valuation has increased to A$7.15 (was A$6.84). SPECULATIVE BUY.

The post Morgans says these ASX shares could deliver 23% to 60% returns appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• Are these rocketing ASX healthcare shares a must buy?
• Is now the time to buy ASX travel shares with brokers tipping up to 100% upside?
• 4 ASX All Ords shares expected to rise 65% to 95% in a year

Motley Fool contributor James Mickleboro has positions in Gqg Partners. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Gqg Partners. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

BHP Group Ltd (ASX: BHP) shares are slipping today.

Shares in the S&P/ASX 200 Index (ASX: XJO) mining giant closed yesterday trading for $60.20. In morning trade on Thursday, shares are swapping hands for $59.86 apiece, down 0.6%.

Goodman Group (ASX: GMG) shares are under pressure as well. Shares in the integrated property group are down 0.8% at the time of writing, trading for $31.45 each.

For some context, the ASX 200 is down 0.7% at this same time, with global stock markets broadly in retreat following renewed military strikes in the Middle East.

Taking a step back, BHP shares have delivered some outsized gains in 2026, while the ASX 200 has shed 1.4%.

Shares in the ASX 200 mining stock have leapt 30.8% year to date. And that’s not including the fully-franked $1.04 per share dividend the miner paid to eligible stockholders on 26 March.

Goodman shares have lagged far behind BHP’s this year, but with the Goodman share price up 2% in 2026, the property giant has materially outperformed the benchmark index. Goodman also paid out a 15 cents per share unfranked dividend on 25 February.

But casting his gaze ahead, Alto Capital’s Tony Locantro believes investors would do well to take profits on both ASX 200 stocks (courtesy of The Bull).

Here’s why.

Time to take profits on BHP shares?

“BHP is Australia’s largest diversified mining company, with significant exposure to iron ore, copper and metallurgical coal,” Locantro said.

And he noted the Aussie mining giant has been ramping up its earnings, driven in part by surging global copper prices and BHP’s increasing exposure to the red metal.

According to Locantro:

The company delivered a strong first half result in fiscal year 2026, reporting underlying EBITDA [earnings before interest, taxes, depreciation and amortisation] of US$15.5 billion, up 25% on the prior corresponding period. A major milestone was copper contributing 51% of group EBITDA for the first time.

While the long-term outlook for copper remains attractive, investor enthusiasm surrounding electrification and AI-related demand has contributed to a strong share price performance.

Explaining his sell recommendation on BHP shares, Locantro said, “In our view, the strong operational result, elevated expectations and risk-reward balance support taking some profits.”

Should I sell Goodman shares?

Alongside his sell recommendation on BHP shares, Locantro also issued a sell recommendation on Goodman shares.

“Goodman Group is a global industrial property and data centre developer with significant exposure to logistics infrastructure and the rapidly expanding artificial intelligence (AI) theme,” he said.

Commenting on Goodman’s H1 FY 2026 results, Locantro noted:

Results highlighted an operating profit of $1.203 billion in the first half of 2026, with data centres representing about 73% of the company’s development pipeline. Total work in progress is expected to reach about $18 billion by June 30, 2026.

However, based on current valuations, Locantro believes investors would do well to take some profits off the table.

He concluded:

While the long-term outlook for digital infrastructure remains highly attractive, investor enthusiasm surrounding AI and data centres has driven a substantial re-rating in the share price. With significant growth expectations already reflected in the valuation, future returns may become increasingly dependent on flawless execution of large-scale projects.

Given the strong share price performance and elevated market expectations, the risk-reward balance supports taking profits at current levels, in our view.

The post Time to cash out? Why this expert is bearish on Goodman and BHP shares appeared first on The Motley Fool Australia.

More reading

• Is this ASX mining stock a better buy than BHP shares?
• Up 58% in a year, are BHP shares still a good buy today?
• Goodman shares rise as another insider sells $18.9 million. Should investors care?
• Do experts rate BHP, Cochlear, and ResMed shares as buys, holds, or sells?
• If you invested $10,000 in BHP shares 10 years ago, here is what they would be worth today

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goodman Group. The Motley Fool Australia has recommended BHP Group and Goodman Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) shares have climbed further into the green in Thursday morning trade.

At the time of writing, the shares are up around 0.5% for the day and trading at $13.57 a piece. The latest increase means Telix shares have now rebounded over 11% from the latest dip in early June, and are now 57% higher from a three-year low recorded in mid-February. For the year to date, Telix shares are now 19% higher.

What has happened to Telix shares this year?

Telix shares tumbled 24% at the start of the year after some disappointing financial results. News of delayed regulatory approvals for key radiopharmaceutical products also dampened investor sentiment.

But it looks like February was a turning point for Telix, and its share price started climbing higher. 

The rebound came off the back of a series of good-news announcements out of the biotech company. 

In late February, the company confirmed that it had filed for a key regulatory approval in Europe. 

Later in March, Telix posted several announcements about its growth and development plans. 

In early April, Telix announced that the FDA had accepted its NDA for TLX101-Px (Pixclara®) and also announced a major collaboration with US-based Regeneron Pharmaceuticals. 

It also announced a 56% increase in revenue and issued FY26 guidance in the range of US$950 million to US$970 million. 

How high can the shares go?

I think there is plenty more room for Telix shares to run this year. And it looks like brokers agree too.

Market Index data shows that all analysts have a strong buy consensus on Telix shares, with a 74% upside to an average target price of $23.60.

It’s a very similar story on TradingView, although analysts expect the share price to climb even higher.

All 17 analysts have a buy or strong buy rating on the shares. The average $24.23 target price implies a potential 80% upside, while the maximum $30.92 target price suggests the stock could climb 129%. That’s more than double the current trading price.

What’s more, I think we could start to see these gains sooner rather than later.

Here’s why.

What could drive Telix shares higher this year?

It’s clear that analysts still view Telix shares as significantly undervalued.

Morgans has a $24.33 price target on the healthcare stock and recently said that industry consolidation could spark additional interest in the company’s shares.

The broker commented that recent news flow on its convertible note refinancing, solid 1Q26 sales, and collaboration with American biotech company Regeneron suggests there is plenty happening at Telix. 

There are also several potential milestones ahead for Telix this year, including FDA clearance for its Zircalix kidney cancer imaging production and Pixclara for brain cancer imaging.

There is plenty of potential ahead for the remainder of 2026.

The post Prediction: I think Telix shares could double in value in 2026. Here’s why appeared first on The Motley Fool Australia.

More reading

• Here are the 10 most shorted ASX shares
• Which are the best ASX shares to buy now for FY27?
• Canaccord Genuity has just added these two ASX 200 shares to its best ideas list
• Here are the top 10 ASX 200 shares today
• Here are the 10 most shorted ASX shares

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Regeneron Pharmaceuticals and Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.